In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse events.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 38560904.
- Also identified by DOI 10.7326/J24-0013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fujiwara Y, Horita N, Adib E, et al. <b>Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials.</b> Lancet Oncol. 2024;25:62-75. 38012893.